Evidence map›Paper›PMID 37652472›Full record

ArticleIn vivo (Athens, Greece)

Humanized PD-1 Knock-in Mice Reveal Nivolumab's Inhibitory Effects on Glioblastoma Tumor Progression

Chun-Yu Chiang, Meng-Chu Huang, Shih-Chong Tsai, Fei-Ting Hsu, Tsai-Lan Liao, Jei-Hwa Yu, Tzu-Hsiang Lin, Hua-Hsih Huang, Pen-An Liao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Chun-Yu Chiang *Ph.D. Program of Electrical and Communications Engineering, Feng Chia University, Taichung, Taiwan, R.O.C.
Meng-Chu Huang *Department of Medical Imaging, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
Shih-Chong TsaiInstitute of Biologics, Development Center for Biotechnology, Taipei, Taiwan, R.O.C.
Fei-Ting HsuDepartment of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.
Tsai-Lan LiaoDepartment of Medical Imaging and Radiologic Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.
Jei-Hwa YuInstitute of Biologics, Development Center for Biotechnology, Taipei, Taiwan, R.O.C.
Tzu-Hsiang LinDepartment of Radiology, Cathay General Hospital, Taipei, Taiwan, R.O.C.
Hua-Hsih Huang *Department of Medical Imaging, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; wyu@show.org.tw.
Pen-An Liao *Department of Radiology, Cathay General Hospital, Taipei, Taiwan, R.O.C.; cgh17508@cgh.org.tw.
Cathay General Hospital · TWChang Bing Show Chwan Memorial Hospital · TWDevelopment Center for Biotechnology · TWCentral Taiwan University of Science and Technology · TWChina Medical University · TWFeng Chia University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimImmunotherapy has been considered a promising approach for brain tumor treatment since the discovery of the brain lymphatic system. Glioblastoma (GBM), the most aggressive type of brain tumor, is associated with poor prognosis and a lack of effective treatment options. MATERIALS AND

methodsTo test the efficacy of human anti-PD-1, we used a humanized PD-1 knock-in mouse to establish an orthotopic GBM-bearing model.

resultsNivolumab, a human anti-PD-1, effectively inhibited tumor growth, increased the survival rate of mice, enhanced the accumulation and function of cytotoxic T cells, reduced the accumulation and function of immunosuppressive cells and their related factors, and did not induce tissue damage or biochemical changes. The treatment also induced the accumulation and activation of CD8

conclusionNivolumab has the potential to be a treatment for GBM.

Indexed as

Brain NeoplasmsGlioblastomaAnimalsBrainCell Line, TumorHumansImmunotherapyMiceNivolumabProgrammed Cell Death 1 ReceptorTumor MicroenvironmentNivolumabProgrammed Cell Death 1 Receptorcytotoxic T cellsGlioblastomahumanized PD-1 knock-in mouseimmune microenvironmentnivolumab

Identifiers

PMID37652472
PMCPMC10500530
OpenAlexW4386337282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.